U.S. Markets open in 6 hrs 47 mins

Takashimaya Company, Limited (TKM.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
7.555-0.079 (-1.035%)
As of 8:17AM CEST. Market open.
People also watch
Full screen
Previous Close7.634
Bid7.553 x 200000
Ask7.929 x 200000
Day's Range7.555 - 7.555
52 Week Range6.412 - 9.142
Avg. Volume5
Market Cap2.84B
PE Ratio (TTM)14.96
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters2 years ago

    Tekmira Ebola drug succeeds in small monkey study

    An experimental Ebola drug from Tekmira Pharmaceuticals Corp cured all three monkeys intentionally infected with the virus, scientists reported on Wednesday, the first such success against the strain of Ebola in West Africa's 2014-2015 outbreak. Similarly, drugs, including Mapp Biopharmaceutical's ZMapp, cured monkeys in lab experiments, but in a strain of Ebola different from that responsible for the current outbreak, the worst ever recorded. "We can't say for certain that an experimental drug that works against one strain will work in another, even if they're almost identical genetically," said Thomas Geisbert of the University of Texas Medical Branch, senior author of the study published in the journal Nature. In the experiment, six rhesus monkeys were infected with huge doses of the Makona strain.

  • Reuters2 years ago

    FDA panel to discuss Ebola vaccine development in May

    The U.S. Food and Drug Administration said an advisory panel will discuss the development of Ebola vaccines, days after an American health worker was flown back after being tested positive for Ebola in Sierra Leone. The federal health regulator would discuss the development of vaccines on May 12, it announced on its website on Wednesday. Mapp Biopharmaceutical's ZMapp and a compound from Tekmira Pharmaceuticals Corp have so far shown they could cure non-human primates given injections of Ebola virus. Other companies that are testing potential treatments for the deadly infection are GlaxoSmithKline, Sarepta Pharmaceuticals Inc, Novavax Inc, Merck & Co and Johnson & Johnson.

  • Reuters2 years ago

    Trial of Tekmira's TKM-Ebola treatment starts in Sierra Leone

    A clinical trial of Tekmira's experimental drug TKM-Ebola-Guinea will start on Wednesday in Sierra Leone, Britain's Wellcome Trust global health charity said. The drug, a so-called "synthetic small interfering RNA (siRNA) therapeutic", is designed specifically to target the strain of Ebola virus causing a vast epidemic centred mainly in Guinea, Liberia and Sierra Leone. An earlier version of the TKM-Ebola drug -- targeted at a different strain -- has already been tested in healthy human volunteers. The efficacy of the Guinea version will now be tested in Ebola patients in a fast-tracked trial funded by Wellcome, with results expected in the second half of this year, the charity said in a statement.